Onkológia 5/2009
Chemotherapy of hormone refractory prostate cancer
Prostate cancer is one of the most frequent malignancies in Slovakia with 1220 cases diagnosed in 2004 and approximately 500 – 550 men dying yearly. Among European countries Slovakia is country with mediate incidence and mortality. Chemotherapy plays role in agressive prostate cancer. Hormone refractory prostate cancer is now regarded as a chemotherapy sensitive tumor. Response is limited. Chemotherapy improves quality of life. TAX 327 and SWOG 99-16 studies demonstrated thad docetaxel-based combinations produced survival improvements.
Keywords: chemotherapy of hormone refractory prostate cancer, chemotherapy, PSA, biological therapy
